{"Title": ["Royalty Pharma Pulls the Off Largest IPO of 2020", "The Implied Analyst 12-Month Target For IWD", "Health Care Sector Update for 06/12/2020: CNC, AGIO, BMY, XLV, IBB", "Got $1,000? Buy These 4 Cancer Stocks", "FDA Mishaps Have Investors Asking \u201cWhat\u2019s Going On With bluebird bio?\u201d", "Noteworthy Monday Option Activity: AGIO, MRNA, KTOS", "Analysts Expect VONE Will Reach $149", "Agios Pharmaceuticals Inc (AGIO) Q1 2020 Earnings Call Transcript", "Royalty Pharma Pulls the Off Largest IPO of 2020", "Interesting AGIO Put And Call Options For June 19th", "Implied RXL Analyst Target Price: $111", "First Week of AGIO November 20th Options Trading", "Oversold Conditions For Agios Pharmaceuticals (AGIO)", "Surprising Analyst 12-Month Target For FNX", "Agios Pharmaceuticals Inc (AGIO) Q4 2019 Earnings Call Transcript", "Surprising Analyst 12-Month Target For FXH", "AGIO Crosses Below Key Moving Average Level", "Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA", "Analysts Expect 17% Gains Ahead For FBT", "Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors", "First Week of January 2020 Options Trading For Agios Pharmaceuticals (AGIO)", "3 \u2018Strong Buy\u2019 Stocks to Buy on Weakness", "Agios Pharmaceuticals Inc (AGIO) Q3 2019 Earnings Call Transcript", "Relative Strength Alert For Agios Pharmaceuticals", "Analysts: 3 Healthcare Stocks That Could Gain 35% \u2014 Or More", "We Did The Math XBI Can Go To $123", "Oversold Conditions For Agios Pharmaceuticals (AGIO)", "Health Care Sector Update for 09/10/2019: XERS,NKTR,PHR,AGIO", "Financial Sector Update for 09/10/2019: NKTR,PHR,AGIO", "First Week of October 18th Options Trading For Agios Pharmaceuticals (AGIO)", "Analysts Predict 18% Gains Ahead For The Holdings of IWS", "Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript", "Interesting AGIO Put And Call Options For December 20th", "RXL's Holdings Could Mean 10% Gain Potential", "First Week of February 2020 Options Trading For Agios Pharmaceuticals (AGIO)", "Health Care Sector Update for 05/16/2019: BLUE,MRTX,AGIO,EDAP,AMGN", "Health Care Sector Update for 05/16/2019: MRTX,AGIO,EDAP", "Health Care Sector Update for 05/16/2019: AGIO, MGNX, NTEC, JNJ, PFE, ABT, MRK, AMGN", "Stock Watch: Agios Pharma Rises On Positive Cholangiocarcinoma Trial Data", "Agios Pharmaceuticals Inc (AGIO) Q1 2019 Earnings Call Transcript", "First Week of AGIO September 20th Options Trading", "Interesting AGIO Put And Call Options For November 15th", "Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report?", "Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer", "Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock", "Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript", "Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates", "Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release", "RSI Alert: Agios Pharmaceuticals (AGIO) Now Oversold", "Agios Pharmaceuticals is Now Oversold (AGIO)", "Could These Be the Next 2 Biotech Buyouts?", "IWB's Underlying Holdings Could Mean 14% Gain Potential", "Analysts Forecast 18% Gains Ahead For IWP", "Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock", "Here's Why I'm Not Selling My Celgene Shares", "Agios Pharmaceuticals (AGIO) Q3 Earnings Preview: Here's What to Look Out For", "5 Biotech Stocks That Could Face M&A Next!", "Agios Pharmaceuticals is Now Oversold (AGIO)", "Could These Be the Next 2 Biotech Buyouts?", "Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position", "Health Care Sector Update for 09/05/2018: HSGX, PRQR, NVS, AGIO, PFE", "Health Care Sector Update for 09/05/2018: DERM,AGIO,PRQR,HSGX,CELG,ESRX,UNH", "Health Care Sector Update for 09/05/2018: AGIO,PRQR,HSGX,CELG", "AGIO Makes Notable Cross Below Critical Moving Average", "Agios Rides on Tibsovo Approval Amid Reliance on Celgene", "Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates", "Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates", "What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?", "First Week of February 2019 Options Trading For Agios Pharmaceuticals (AGIO)", "Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug", "Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo", "Health Care Sector Update for 07/12/2018: AGIO,XENE,AUPH,AUP.TO,MYOV,ACRX", "Agios Pharmaceuticals Becomes Oversold (AGIO)", "Implied IYH Analyst Target Price: $205", "Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug", "Notable Thursday Option Activity: AGIO, PBYI, REGN", "Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason", "Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue?", "Noteworthy Wednesday Option Activity: AGIO, PXD, JILL", "Agios (AGIO) Progressing Well on Pipeline Amid Competition", "Agios Out-Licenses China Rights to Leukemia Drug Tibsovo", "Implied IYH Analyst Target Price: $205", "Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss", "Why Earnings Season Could Be Great for Agios (AGIO)", "Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?", "Agios Pharmaceuticals Reaches Analyst Target Price", "Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline", "The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte", "Health Care Sector Update for 05/23/2018: AGIO,ARDX,RMTI,ACHV", "Agios Pharmaceuticals Shares Rise on Buyout Speculation", "Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today", "Monday's ETF Movers: FBT, SDIV", "AGIO December 21st Options Begin Trading", "Interesting AGIO Put And Call Options For November 16th", "FBT, AVXS, XON, AGIO: ETF Outflow Alert", "Near a 3-Year Low, Is Celgene Stock a Buy?", "Pharma M&A Active This Week: 4 Potential Buyout Targets", "Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y", "Health Care Sector Update for 02/14/2018: JNJ, PFE, ABT, MRK, AMGN, PIRS, ZSAN, IQV, AGIO, BMY, NKTR", "Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Why Agios Pharmaceuticals Shares Jumped 37.8% in January", "3 Strong Stocks to Buy in a Volatile Market", "Agios Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90", "FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review", "Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?", "Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year", "Health Care Sector Update for 01/19/2018: JNJ, PFE, ABT, MRK, AMGN, PAVM, ACOR, OBLN, AGIO, CHEK", "Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating", "Celgene Provides 2017 Preliminary Results & 2018 View", "Celgene to Acquire Impact Biomedicines to Boost Pipeline", "Implied FBT Analyst Target Price: $151", "What's in the Cards for Varian Medical (VAR) in Q1 Earnings?", "Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA", "Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.", "Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo", "Celgene (CELG) Down on Discouraging Data on Revlimid", "Agios Pharmaceuticals is Now Oversold (AGIO)", "Why This Biotech Stock Is Defying A Hematology-Related Pitfall", "IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength", "Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?", "Agios Posts New Data on Glioma Candidate from Dose Expansion", "7 \u2018Strong Buy\u2019 Stocks With 100% Wall Street Support", "Health Care Sector Update for 11/17/2017: AGIO", "Noteworthy Thursday Option Activity: AVGO, AGIO, RDFN", "Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y", "Agios (AGIO) Q3 Loss Narrower than Expected, Sales Beat", "Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?", "Agios Pharmaceuticals Enters Oversold Territory (AGIO)", "Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View", "Is Celgene (CELG) Poised for a Beat This Earnings Season?", "Agios Pharmaceuticals Inc (AGIO) CEO David P Schenkein Sold $5.6 million of Shares", "We Did The Math FBT Can Go To $141", "Why You Can Back Up the Truck and Load Up on This Biotech Stock", "Analysts Expect EQWM Will Reach $49", "Why I Love Celgene Corporation", "Commit To Purchase Agios Pharmaceuticals At $55, Earn 15.6% Annualized Using Options", "Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View", "Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More", "Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?", "4 Medical Product Stocks Likely to Top Q2 Earnings Estimates", "Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?", "Agios Pharmaceuticals Reaches Analyst Target Price", "Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session", "Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y", "Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote", "Key FDA Events to Watch Out for in Aug 2017", "Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View", "Commit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options", "What's in Store for Agios Pharma (AGIO) in Q2 Earnings?", "Is Celgene (CELG) Poised For a Beat This Earnings Season?", "Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China", "3 Reasons the Best Is Yet to Come for Celgene", "Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial", "Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?", "Celgene and Agios Announce Data on Idhifa for Leukemia", "Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review", "The Math Shows IYH Can Go To $175", "3 Stocks To Buy When The Market's Crashing", "Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus", "Agios/Celgene's Leukemia Candidate Positive in Phase I/II", "3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash", "Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?", "Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View", "The 1 Stock I'd Buy Right Now", "Commit To Buy Agios Pharmaceuticals At $35, Earn 9.4% Annualized Using Options", "Liberty Sirius XM Group (LSXMK) Lead 12 Activist Investor Reports", "Key Factors to Look Out for in Celgene's (CELG) Q1 Results", "Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y", "Tuesday's ETF Movers: ITB, FBT", "3 Cancer Drug Stocks That Could Make You Rich", "3 Rock-Solid Stocks to Buy Before the Next Market Crash", "3 Perfect Stocks You Can Buy Now", "Analysts Anticipate FBT Will Reach $122", "Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?", "Monday's ETF Movers: FBT, XRT", "9 Reasons Celgene Could Be the World's Most Perfect Stock", "Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y", "Implied IYH Analyst Target Price: $169", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)", "Commit To Purchase Agios Pharmaceuticals At $35, Earn 17.8% Annualized Using Options", "Why Agios Pharmaceuticals Sank 34.4% in 2016", "Implied IYH Analyst Target Price: $169", "Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up", "Why Agios Pharmaceuticals Inc. Got Hammered Today", "Health Care Sector Update for 12/16/2016: AGIO,EVOK,RXII", "3 Drugs Heading to the FDA Soon", "Agios Presents Data from Dose Expansion Study of AG-120", "Agios Pharmaceuticals Reaches Analyst Target Price", "Agios (AGIO) Posts Wider-than-Expected Loss in Q3", "Why Celgene Corp Is a Better Buy Than Gilead Sciences", "Agios Stops Development of PKR Activator AG-519, Stock Falls", "Agios (AGIO): Will the Stock Disappoint in Q3 Earnings?", "Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations", "Is Celgene the Smartest Buyer in Biotech?", "Analysts Forecast 14% Upside For IYH", "Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up", "Wednesday's ETF Movers: FBT, GDXJ", "Notable Wednesday Option Activity: TRGP, AGIO, WFM", "Medical Product Nov 3 Earnings Preview: HRC, AGIO, PEN, PODD", "The 1 Stock You've Been Overlooking for Your Roth IRA", "Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus", "Agios (AGIO) Reports Wider-than-Expected Loss in Q2", "Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More", "Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?", "3 Biotech Stocks to Buy on Sale", "Why Agios Pharmaceuticals Inc Stock Skyrocketed Today", "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016", "Commit To Purchase Agios Pharmaceuticals At $35, Earn 15.6% Annualized Using Options", "Agios Reports Favorable Phase II PK Deficiency Study Data", "This Is Why Agios Pharmaceuticals' Stock Rose 14.3% in May", "Why Agios Pharmaceuticals Inc. Presented Lower Today", "Thursday's ETF Movers: GDXJ, XBI", "AGIO Crosses Above Key Moving Average Level", "First Week of July 15th Options Trading For Agios Pharmaceuticals (AGIO)", "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016", "Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus", "Agios (AGIO) Reports Narrower-than-Expected Loss in Q1", "What's in Store for Agios (AGIO) This Earnings Season?", "Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?", "Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?", "Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?", "Agios Strikes Metabolic Immuno-Oncology Deal with Celgene", "First Week of November 18th Options Trading For Agios Pharmaceuticals (AGIO)", "Interesting AGIO Put And Call Options For April 15th", "New Strong Sell Stocks for February 22nd", "Agios' (AGIO) Q4 Loss Wider than Expected, Pipeline in Focus", "Agios (AGIO) Reports Wider-than-Expected Loss in Q4", "Health Care Sector Update for 02/18/2016: AGIO, ZFGN", "Agios (AGIO) Q4 Earnings Preview: Will it Disappoint Again?", "Wednesday's ETF Movers: XBI, XLU", "Top Biotechs for 2016", "Tuesday's ETF Movers: XOP, FBT", "Health Care Sector Update for 01/21/2016: AGIO, ACRX", "XBI, CPHD, AGIO, MDVN: Large Outflows Detected at ETF", "Agios (AGIO) Provides Pipeline Updates and 2016 Strategy", "Notable ETF Outflow Detected - XBI, AGIO, CPHD, RARE", "Tuesday's ETF Movers: OIH, XBI", "The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January", "Expectations for Perfection Haunt Agios Pharmaceuticals Inc. in November", "Noteworthy Monday Option Activity: EBIX, DECK, AGIO", "Second Cancer Incidence Rates Have Doubled, and a Catch-22 Has Emerged", "1 Healthcare Stock That Has It All", "Health Care Sector Update for 11/09/2015: AGIO,LOXO,AVXL", "Agios' (AGIO) Q3 Loss Wider than Expected, Pipeline in Focus", "Agios (AGIO) Reports Wider-than-Expected Loss in Q3", "The 3 Most Important Drugs in Celgene's Pipeline", "Agios Pharmaceuticals (AGIO) in Focus: Stock Rises 24.8%", "Health Care Sector Update for 10/27/2015: AGIO,TRIV,ELGX,ORPN", "Health Care Sector Update for 10/27/2015: AGIO,TRIV,ELGX,ORPN", "Tuesday's ETF Movers: FBT, XOP", "First Week of December 18th Options Trading For Agios Pharmaceuticals (AGIO)", "Agios (AGIO) Provides Pipeline Update, AG-221 in Focus", "Agios Pharmaceuticals Enters Oversold Territory (AGIO)", "Will Agios (AGIO) Disappoint Investors this Earnings Season?", "Agios Pharmaceuticals is Now Oversold (AGIO)", "Agios Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for AGIO", "DexCom (DXCM) Q2 Loss Wider than Expected, Revenues Beat - Analyst Blog", "Has Allscripts' Q2 Earnings Results Disappointed Investors? - Analyst Blog", "Agios (AGIO) Reports Wider-than-Expected Loss in Q2 - Tale of the Tape", "SurModics (SRDX) Beats on Q3 Earnings, Improves Outlook - Analyst Blog", "Alere Lags Q2 Earnings, Revenues Down Y/Y; Margins Expand - Analyst Blog", "First Week of AGIO October 16th Options Trading", "Pacific Biosciences (PACB) Q2 Earnings: What's in Store? - Analyst Blog", "Outfront Media (OUT) to Report Earnings: What to Expect? - Analyst Blog", "Is Agios (AGIO) Poised to Beat Estimates in Q2 Earnings? - Analyst Blog", "3 MedTech Stocks to Buy Before Their Q2 Earnings - Earnings ESP", "Community Health Q2 Earnings Beat, Surge Y/Y; View Revised - Analyst Blog", "Luminex (LMNX) Tops Q2 Earnings, Revenues; Pipeline Strong - Analyst Blog", "Will ARIAD (ARIA) Disappoint Estimates this Earnings Season? - Analyst Blog", "Thoratec Beats on Q2 Earnings & Revenues, Pipeline Strong - Analyst Blog", "Will Ligand Pharmaceuticals (LGND) Beat Earnings in Q2? - Analyst Blog", "Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog", "Will Cerner's (CERN) Earnings Pull a Surprise in Q2? - Analyst Blog", "Will BioMarin Top Q2 Earnings Again on Vimizim Sales? - Analyst Blog", "Will DENTSPLY (XRAY) Beat Earnings on Pipeline Strength? - Analyst Blog", "Can Cardinal Health's (CAH) Q4 Earnings Pull a Surprise? - Analyst Blog", "Will Ecolab (ECL) Earnings Take Investors by Surprise in Q2? - Analyst Blog", "Will Becton, Dickinson (BDX) Earnings Pull a Surprise in Q3? - Analyst Blog", "XOMA Crashes after Gevokizumab Misses Primary Endpoint - Analyst Blog", "Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog", "AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog", "Can C.R. Bard (BCR) Surprise Earnings Estimates in Q2? - Analyst Blog", "AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog", "Amgen Reports Positive Data on Leukemia Drug Blincyto - Analyst Blog", "Hill-Rom-Welch Allyn Acquisition Deal Wins FTC Clearance - Analyst Blog", "St. Jude to Acquire Thoratec for $3.4B: Potent Combination? - Analyst Blog", "AstraZeneca's (AZN) Oncology Drug Iressa Label Expanded - Analyst Blog", "AbbVie (ABBV) Gains on Label Expansion of Imbruvica in EU - Analyst Blog", "TG Therapeutics (TGTX) Looks Good: Stock Adds 5.8% - Tale of the Tape", "AstraZeneca Divests Ex-U.S. Rights to Entocort for $215M - Analyst Blog", "What Falling Estimates & Price Mean for Baxter International (BAX) - Tale of the Tape", "New Strong Buy Stocks for July 8th - Tale of the Tape", "Agios Doses First Patient with AG-881 in Early-Stage Study - Analyst Blog", "2 Reasons Why Medtronic Should Draw Investors' Attention Now - Analyst Blog", "These 3 Biotech Stocks Are Losing Money, But We'd Still Buy Them", "Agios Reports New Data on Hematologic Malignancy Drugs - Analyst Blog", "Why Agios Pharmaceuticals Inc. Shares Were Throttled", "Friday's ETF Movers: FM, FBT", "Agios Gets Orphan Drug Designation from FDA for AG-120 - Analyst Blog", "Why You Shouldn't Bet Against Agios Pharmaceuticals (AGIO) Stock - Tale of the Tape", "Use Options For a Chance To Buy AGIO at a 25% Discount", "2 Stocks to Buy Now in Biotech", "These 3 Biotech Stocks Are Losing Money, But We'd Still Buy Them", "Agios Reports New Data on Hematologic Malignancy Drugs - Analyst Blog", "Agios Gains on Fast Track Status for Leukemia Drug AG-120 - Analyst Blog", "Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape", "Company News for May 08, 2015 - Corporate Summary", "Agios (AGIO) Reports Narrower-than-Expected Loss in Q1 - Tale of the Tape", "Mutual Fund Manager Columbia Wanger Adds 4 Stocks in Q1", "Can the Uptrend Continue for Agios Pharmaceuticals (AGIO)? - Tale of the Tape", "Health Care Sector Update for 04/30/2015: WX, AGIO, CAH", "Biotech Bubble Bursting? 3 Stocks I Want to Buy", "Commit To Purchase Agios Pharmaceuticals At $80, Earn 21.6% Annualized Using Options", "Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog", "What Makes Agios Pharmaceuticals (AGIO) a Strong Sell? - Tale of the Tape", "The 1 Stock You've Been Overlooking for Your Roth IRA", "Company News for February 18, 2015 - Corporate Summary", "Will Agios (AGIO) Disappoint this Earnings Season? - Analyst Blog", "Agios (AGIO) Reports Wider-than-Expected Loss in Q4 - Tale of the Tape", "Why Agios Pharmaceuticals Inc Shares Burst Today", "Will Agios (AGIO) Surprise Estimates This Earnings Season? - Analyst Blog", "Pre-Market Earnings Report for February 17, 2015 : MDT, WM, GPC, MGM, NCLH, GT, LECO, WRI, AGIO, WWW, NHI, ALE", "7 Companies We'd Buy and Hold for the Next 20 Years", "The Top Healthcare Stock to Buy in February", "Celgene Corp.'s Expanding Margins", "Health Care Sector Update for 02/17/2015: AGIO, PFE", "A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week", "Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape", "The Surprising Thing Most of 2014's Top 10 Stocks Have in Common", "These 3 Biotech Stocks Tripled Investors' Money in 2014", "The Market's Top 10 Stocks of 2014", "These 3 Biotechs Are Looking at a Happy New Year", "Notable ETF Outflow Detected - XBI, AGIO, BLUE, RCPT", "5 Cant-Miss Reasons Why Celgene Corporation Could Soar", "3 Traits of the Best Healthcare Stocks in 2014", "Use Options For a Chance To Buy AGIO at a 32% Discount", "Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape", "Futures Lower As Global Growth Concerns Triggered Overseas", "Health Care Sector Update for 12/08/2014: ARIA, AGIO, ADXS, KND", "Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog", "3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't", "Tuesday Sector Laggards: Drugs, Biotechnology Stocks", "Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog", "Health Care Sector Update for 11/19/2014: AGIO,AEMD,BIND", "Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog", "Pre-Market Earnings Report for November 7, 2014 : BAM, HUM, BPL, ICPT, ISIS, STAY, AGIO, ERF, LXP, CTB, SJI, CCOI", "Can Celgene Corporation Stock Motor to $150 Following Earnings?", "Forget MannKind Corporation: 3 Better Stocks", "Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog", "3 Top Large-Cap Biotech Stocks for 2015", "Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog", "Sector Update: Health Care", "NASDAQ Biotech Top Performers (Pre-Open September 19)", "Agios Pharmaceuticals director buys 2,300 shares", "Wednesday 6/25 Insider Buying Report: SAFT, AGIO", "Monday's ETF Movers: GDXJ, IBB", "Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog", "Agios Initiates Trial on AG-348 - Analyst Blog", "Friday 5/2 Insider Buying Report: OKSB, AGIO", "Zacks Rank #5 Additions for Tuesday - Tale of the Tape", "Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape", "Sector Update: Healthcare Shares Mixed Pre-Market; Quest Diagnostic Results Top Street View", "Sector Update: Healthcare", "Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog", "Agios Presents Data on AG-221 - Analyst Blog", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Zacks Rank #5 Additions for Tuesday - Tale of the Tape", "Zacks Rank #5 Additions for Thursday - Tale of the Tape", "Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% - Tale of the Tape", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape", "Friday's ETF with Unusual Volume: IBB", "Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher - Tale of the Tape", "Sector Update: Healthcare", "Agios Pharmaceuticals (AGIO) Surges: Stock Moves 18.6% Higher - Tale of the Tape", "Biotech IPOs are back to normal", "Pipeline Progress at Agios Pharma - Analyst Blog", "US IPO Recap: 11 deals price in busiest week since November 2007, seven companies set terms", "Agios Pharmaceuticals prices IPO at $18, above the range", "Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues", "Healthcare Stocks Turn Lower This Afternoon; Agios Pharma Climbs After Beating Q4 Revenue Estimates", "12 US IPOs planned for the week of Jul 22", "Biotech Agios Pharmaceuticals sets terms for $75 million IPO", "Four More IPOs Today"], "Elapsed Time": ["JUN 16, 2020", "JUN 15, 2020", "JUN 12, 2020", "JUN 8, 2020", "MAY 22, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 1, 2020", "JUN 16, 2020", "APR 24, 2020", "APR 8, 2020", "MAR 27, 2020", "MAR 12, 2020", "MAR 2, 2020", "FEB 13, 2020", "JAN 28, 2020", "APR 30, 2020", "JAN 13, 2020", "DEC 26, 2019", "NOV 27, 2019", "NOV 19, 2019", "NOV 14, 2019", "NOV 1, 2019", "OCT 31, 2019", "JAN 17, 2020", "OCT 17, 2019", "SEP 30, 2019", "SEP 10, 2019", "SEP 10, 2019", "SEP 4, 2019", "AUG 15, 2019", "AUG 5, 2019", "OCT 22, 2019", "JUL 15, 2019", "JUN 26, 2019", "MAY 16, 2019", "MAY 16, 2019", "MAY 16, 2019", "MAY 15, 2019", "MAY 2, 2019", "AUG 1, 2019", "APR 1, 2019", "MAR 16, 2019", "FEB 21, 2019", "FEB 15, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 7, 2019", "APR 17, 2019", "DEC 20, 2018", "DEC 8, 2018", "DEC 3, 2018", "NOV 2, 2018", "NOV 2, 2018", "OCT 26, 2018", "OCT 25, 2018", "JAN 10, 2019", "DEC 20, 2018", "SEP 13, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 5, 2018", "AUG 10, 2018", "OCT 19, 2018", "AUG 3, 2018", "AUG 2, 2018", "JUL 30, 2018", "JUL 26, 2018", "JUL 25, 2018", "JUL 23, 2018", "JUL 12, 2018", "AUG 8, 2018", "JUN 27, 2018", "JUN 20, 2018", "JUN 14, 2018", "JUN 5, 2018", "JUN 4, 2018", "MAY 30, 2018", "MAY 24, 2018", "JUN 27, 2018", "MAY 7, 2018", "MAY 4, 2018", "MAY 3, 2018", "APR 30, 2018", "APR 19, 2018", "APR 18, 2018", "APR 16, 2018", "MAY 23, 2018", "APR 10, 2018", "APR 9, 2018", "APR 9, 2018", "APR 4, 2018", "APR 3, 2018", "MAR 15, 2018", "MAR 13, 2018", "APR 13, 2018", "FEB 15, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 9, 2018", "FEB 7, 2018", "FEB 2, 2018", "JAN 23, 2018", "FEB 16, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 19, 2018", "JAN 11, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 22, 2018", "DEC 29, 2017", "DEC 27, 2017", "DEC 27, 2017", "DEC 22, 2017", "DEC 14, 2017", "DEC 12, 2017", "DEC 5, 2017", "DEC 29, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 9, 2017", "NOV 2, 2017", "NOV 1, 2017", "OCT 27, 2017", "NOV 20, 2017", "OCT 26, 2017", "OCT 23, 2017", "OCT 5, 2017", "SEP 25, 2017", "AUG 27, 2017", "AUG 16, 2017", "AUG 15, 2017", "OCT 26, 2017", "OCT 26, 2017", "AUG 7, 2017", "AUG 7, 2017", "AUG 7, 2017", "AUG 4, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 9, 2017", "AUG 2, 2017", "AUG 1, 2017", "JUL 27, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 24, 2017", "JUL 6, 2017", "AUG 2, 2017", "JUN 15, 2017", "JUN 8, 2017", "JUN 7, 2017", "JUN 1, 2017", "MAY 30, 2017", "MAY 18, 2017", "MAY 5, 2017", "JUN 27, 2017", "MAY 3, 2017", "MAY 1, 2017", "APR 27, 2017", "APR 26, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "MAY 4, 2017", "APR 18, 2017", "APR 17, 2017", "APR 13, 2017", "APR 7, 2017", "MAR 23, 2017", "MAR 20, 2017", "MAR 20, 2017", "APR 24, 2017", "FEB 16, 2017", "FEB 16, 2017", "FEB 10, 2017", "JAN 13, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 9, 2017", "FEB 17, 2017", "DEC 16, 2016", "DEC 16, 2016", "DEC 12, 2016", "NOV 21, 2016", "NOV 15, 2016", "NOV 3, 2016", "NOV 3, 2016", "DEC 19, 2016", "OCT 31, 2016", "OCT 13, 2016", "SEP 30, 2016", "SEP 27, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 7, 2016", "NOV 2, 2016", "AUG 11, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 2, 2016", "JUL 30, 2016", "SEP 7, 2016", "JUL 3, 2016", "JUN 21, 2016", "JUN 13, 2016", "JUN 10, 2016", "JUN 9, 2016", "JUN 9, 2016", "JUN 2, 2016", "JUL 14, 2016", "MAY 18, 2016", "MAY 6, 2016", "MAY 5, 2016", "MAY 3, 2016", "APR 28, 2016", "APR 27, 2016", "APR 27, 2016", "MAY 18, 2016", "MAR 23, 2016", "FEB 25, 2016", "FEB 22, 2016", "FEB 19, 2016", "FEB 18, 2016", "FEB 18, 2016", "FEB 16, 2016", "APR 6, 2016", "JAN 28, 2016", "JAN 26, 2016", "JAN 21, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 4, 2016", "DEC 22, 2015", "FEB 6, 2016", "DEC 9, 2015", "DEC 7, 2015", "DEC 6, 2015", "NOV 26, 2015", "NOV 9, 2015", "NOV 6, 2015", "NOV 5, 2015", "DEC 21, 2015", "OCT 28, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 22, 2015", "OCT 22, 2015", "SEP 29, 2015", "NOV 4, 2015", "AUG 14, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 5, 2015", "SEP 28, 2015", "AUG 5, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 5, 2015", "AUG 3, 2015", "AUG 3, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 24, 2015", "AUG 3, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 20, 2015", "JUL 20, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 23, 2015", "JUL 14, 2015", "JUL 13, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 9, 2015", "JUL 8, 2015", "JUN 25, 2015", "JUL 16, 2015", "JUN 21, 2015", "JUN 15, 2015", "JUN 12, 2015", "JUN 12, 2015", "JUN 11, 2015", "MAY 28, 2015", "MAY 27, 2015", "JUN 22, 2015", "JUN 21, 2015", "JUN 15, 2015", "MAY 19, 2015", "MAY 15, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 5, 2015", "MAY 27, 2015", "APR 30, 2015", "APR 27, 2015", "APR 14, 2015", "MAR 26, 2015", "FEB 24, 2015", "FEB 20, 2015", "FEB 18, 2015", "MAY 5, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 16, 2015", "FEB 13, 2015", "FEB 6, 2015", "FEB 1, 2015", "JAN 29, 2015", "FEB 17, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 11, 2015", "JAN 4, 2015", "JAN 3, 2015", "DEC 31, 2014", "DEC 24, 2014", "JAN 26, 2015", "DEC 15, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 7, 2014", "DEC 23, 2014", "NOV 20, 2014", "NOV 19, 2014", "NOV 6, 2014", "NOV 6, 2014", "OCT 28, 2014", "OCT 27, 2014", "OCT 16, 2014", "DEC 6, 2014", "NOV 20, 2014", "SEP 26, 2014", "SEP 19, 2014", "JUN 25, 2014", "JUN 25, 2014", "JUN 23, 2014", "SEP 29, 2014", "JUN 10, 2014", "MAY 2, 2014", "APR 29, 2014", "APR 25, 2014", "APR 24, 2014", "APR 24, 2014", "APR 9, 2014", "JUN 16, 2014", "APR 7, 2014", "MAR 25, 2014", "MAR 13, 2014", "MAR 12, 2014", "MAR 10, 2014", "MAR 7, 2014", "MAR 7, 2014", "APR 8, 2014", "MAR 6, 2014", "JAN 16, 2014", "NOV 25, 2013", "SEP 24, 2013", "JUL 26, 2013", "JUL 24, 2013", "JUL 24, 2013", "MAR 6, 2014", "JUL 22, 2013", "JUL 12, 2013", "JUL 24, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/royalty-pharma-pulls-the-off-largest-ipo-of-2020-2020-06-16", "https://www.nasdaq.com/articles/the-implied-analyst-12-month-target-for-iwd-2020-06-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-12-2020%3A-cnc-agio-bmy-xlv-ibb-2020-06-12", "https://www.nasdaq.com/articles/got-%241000-buy-these-4-cancer-stocks-2020-06-08", "https://www.nasdaq.com/articles/fda-mishaps-have-investors-asking-whats-going-on-with-bluebird-bio-2020-05-22", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-agio-mrna-ktos-2020-05-11", "https://www.nasdaq.com/articles/analysts-expect-vone-will-reach-%24149-2020-05-11", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q1-2020-earnings-call-transcript-2020-05-01", "https://www.nasdaq.com/articles/royalty-pharma-pulls-the-off-largest-ipo-of-2020-2020-06-16", "https://www.nasdaq.com/articles/interesting-agio-put-and-call-options-for-june-19th-2020-04-24", "https://www.nasdaq.com/articles/implied-rxl-analyst-target-price%3A-%24111-2020-04-08", "https://www.nasdaq.com/articles/first-week-of-agio-november-20th-options-trading-2020-03-27", "https://www.nasdaq.com/articles/oversold-conditions-for-agios-pharmaceuticals-agio-2020-03-12", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-fnx-2020-03-02", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q4-2019-earnings-call-transcript-2020-02-14", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-fxh-2020-01-28", "https://www.nasdaq.com/articles/agio-crosses-below-key-moving-average-level-2020-04-30", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-shares-cross-below-200-dma-2020-01-13", "https://www.nasdaq.com/articles/analysts-expect-17-gains-ahead-for-fbt-2019-12-26", "https://www.nasdaq.com/articles/agios-pharmaceuticals-raised-%24294-million-to-fight-cancer-and-rare-genetic-diseases%3A-what", "https://www.nasdaq.com/articles/first-week-of-january-2020-options-trading-for-agios-pharmaceuticals-agio-2019-11-19", "https://www.nasdaq.com/articles/3-strong-buy-stocks-to-buy-on-weakness-2019-11-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q3-2019-earnings-call-transcript-2019-11-01", "https://www.nasdaq.com/articles/relative-strength-alert-for-agios-pharmaceuticals-2019-10-31", "https://www.nasdaq.com/articles/analysts%3A-3-healthcare-stocks-that-could-gain-35-or-more-2020-01-17", "https://www.nasdaq.com/articles/we-did-the-math-xbi-can-go-to-%24123-2019-10-17", "https://www.nasdaq.com/articles/oversold-conditions-for-agios-pharmaceuticals-agio-2019-09-30", "https://www.nasdaq.com/articles/health-care-sector-update-for-09-10-2019%3A-xersnktrphragio-2019-09-10", "https://www.nasdaq.com/articles/financial-sector-update-for-09-10-2019%3A-nktrphragio-2019-09-10", "https://www.nasdaq.com/articles/first-week-of-october-18th-options-trading-for-agios-pharmaceuticals-agio-2019-09-04", "https://www.nasdaq.com/articles/analysts-predict-18-gains-ahead-for-the-holdings-of-iws-2019-08-15", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q2-2019-earnings-call-transcript-2019-08-06", "https://www.nasdaq.com/articles/interesting-agio-put-and-call-options-for-december-20th-2019-10-22", "https://www.nasdaq.com/articles/rxls-holdings-could-mean-10-gain-potential-2019-07-15", "https://www.nasdaq.com/articles/first-week-of-february-2020-options-trading-for-agios-pharmaceuticals-agio-2019-06-26", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-16-2019%3A-bluemrtxagioedapamgn-2019-05-16", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-16-2019%3A-mrtxagioedap-2019-05-16", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-16-2019%3A-agio-mgnx-ntec-jnj-pfe-abt-mrk-amgn-2019-05-16", "https://www.nasdaq.com/articles/stock-watch%3A-agios-pharma-rises-positive-cholangiocarcinoma-trial-data-2019-05-15", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q1-2019-earnings-call-transcript-2019-05-02", "https://www.nasdaq.com/articles/first-week-of-agio-september-20th-options-trading-2019-08-01", "https://www.nasdaq.com/articles/interesting-agio-put-and-call-options-november-15th-2019-04-01", "https://www.nasdaq.com/articles/why-is-agios-pharmaceuticals-agio-up-13.2-since-last-earnings-report-2019-03-16", "https://www.nasdaq.com/articles/agios-tibsovo-gets-fda-priority-review-in-first-line-cancer-2019-02-21", "https://www.nasdaq.com/articles/agios-agio-q4-earnings-beat-tibsovo-sales-push-up-stock-2019-02-15", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-q4-2018-earnings-conference-call-transcript-2019-02-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-reports-q4-loss-tops-revenue-estimates-2019-02-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-may-report-negative-earnings%3A-know-the-trend-ahead-of-next", "https://www.nasdaq.com/articles/rsi-alert-agios-pharmaceuticals-agio-now-oversold-2019-04-17", "https://www.nasdaq.com/articles/agios-pharmaceuticals-now-oversold-agio-2018-12-20", "https://www.nasdaq.com/articles/could-these-be-next-2-biotech-buyouts-2018-12-08", "https://www.nasdaq.com/articles/iwbs-underlying-holdings-could-mean-14-gain-potential-2018-12-03", "https://www.nasdaq.com/articles/analysts-forecast-18-gains-ahead-iwp-2018-11-02", "https://www.nasdaq.com/articles/agios-agio-q3-earnings-beat-tibsovo-sales-drive-stock-2018-11-02", "https://www.nasdaq.com/articles/heres-why-im-not-selling-my-celgene-shares-2018-10-26", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q3-earnings-preview%3A-heres-what-to-look-out-for-2018-10-25", "https://www.nasdaq.com/articles/5-biotech-stocks-could-face-ma-next-2019-01-10", "https://www.nasdaq.com/articles/agios-pharmaceuticals-now-oversold-agio-2018-12-20", "https://www.nasdaq.com/articles/3-biotech-stocks-analysts-say-are-market-winners-2018-09-13", "https://www.nasdaq.com/articles/agios-agio-assigns-ex-celgene-executive-to-ceo-position-2018-09-05", "https://www.nasdaq.com/articles/health-care-sector-update-09052018-hsgx-prqr-nvs-agio-pfe-2018-09-05", "https://www.nasdaq.com/articles/health-care-sector-update-09052018-dermagioprqrhsgxcelgesrxunh-2018-09-05", "https://www.nasdaq.com/articles/health-care-sector-update-09052018-agioprqrhsgxcelg-2018-09-05", "https://www.nasdaq.com/articles/agio-makes-notable-cross-below-critical-moving-average-2018-08-10", "https://www.nasdaq.com/articles/agios-rides-on-tibsovo-approval-amid-reliance-on-celgene-2018-10-19", "https://www.nasdaq.com/articles/agios-agio-q2-loss-narrows-revenues-surpass-estimates-2018-08-03", "https://www.nasdaq.com/articles/agios-agio-q2-loss-narrows-revenue-beat-estimates-2018-08-02", "https://www.nasdaq.com/articles/whats-in-the-cards-for-agios-agio-stock-in-q2-earnings-2018-07-30", "https://www.nasdaq.com/articles/first-week-february-2019-options-trading-agios-pharmaceuticals-agio-2018-07-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biogen-gains-on-q2-results-agios-gets-fda-nod-for-leukemia-drug", "https://www.nasdaq.com/articles/agios-agio-secures-fda-approval-for-leukemia-drug-tibsovo-2018-07-23", "https://www.nasdaq.com/articles/health-care-sector-update-07122018-agioxeneauphauptomyovacrx-2018-07-12", "https://www.nasdaq.com/articles/agios-pharmaceuticals-becomes-oversold-agio-2018-08-08", "https://www.nasdaq.com/articles/implied-iyh-analyst-target-price-205-2018-06-27", "https://www.nasdaq.com/articles/agios-agio-initiates-phase-iii-study-on-pk-deficiency-drug-2018-06-20", "https://www.nasdaq.com/articles/notable-thursday-option-activity-agio-pbyi-regn-2018-06-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-incstock-analyst-darling-good-reason-2018-06-05", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-up-13.4-since-earnings-report%3A-can-it-continue-2018-06-04", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-agio-pxd-jill-2018-05-30", "https://www.nasdaq.com/articles/agios-agio-progressing-well-on-pipeline-amid-competition-2018-05-24", "https://www.nasdaq.com/articles/agios-out-licenses-china-rights-to-leukemia-drug-tibsovo-2018-06-27", "https://www.nasdaq.com/articles/agios-agio-q1-loss-wider-than-expected-revenues-miss-2018-05-07", "https://www.nasdaq.com/articles/agios-agio-q1-loss-wider-than-expected-sales-miss-2018-05-04", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-agios-agio-2018-05-03", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-agios-agio-in-q1-earnings-2018-04-30", "https://www.nasdaq.com/articles/agios-pharmaceuticals-reaches-analyst-target-price-2018-04-19", "https://www.nasdaq.com/articles/agios-leukemia-drug-bodes-well-for-growth-strong-pipeline-2018-04-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-agios-pharmaceuticals-biomarin-pharmaceutical-vertex", "https://www.nasdaq.com/articles/health-care-sector-update-05232018-agioardxrmtiachv-2018-05-23", "https://www.nasdaq.com/articles/agios-pharmaceuticals-shares-rise-on-buyout-speculation-2018-04-10", "https://www.nasdaq.com/articles/why-alcoa-merck-and-agios-pharmaceuticals-jumped-today-2018-04-09", "https://www.nasdaq.com/articles/mondays-etf-movers-fbt-sdiv-2018-04-09", "https://www.nasdaq.com/articles/agio-december-21st-options-begin-trading-2018-04-04", "https://www.nasdaq.com/articles/interesting-agio-put-and-call-options-november-16th-2018-04-03", "https://www.nasdaq.com/articles/fbt-avxs-xon-agio-etf-outflow-alert-2018-03-15", "https://www.nasdaq.com/articles/near-3-year-low-celgene-stock-buy-2018-03-13", "https://www.nasdaq.com/articles/pharma-ma-active-week-4-potential-buyout-targets-2018-04-13", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-revenues-slump-y-y-2018-02-15", "https://www.nasdaq.com/articles/health-care-sector-update-02142018-jnj-pfe-abt-mrk-amgn-pirs-zsan-iqv-agio-bmy-nktr-2018", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-sales-miss-2018-02-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2018-02-09", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-shares-jumped-378-january-2018-02-07", "https://www.nasdaq.com/articles/3-strong-stocks-to-buy-in-a-volatile-market-2018-02-02", "https://www.nasdaq.com/articles/agios-pharmaceuticals-joins-rank-stocks-rs-ratings-over-90-2018-01-23", "https://www.nasdaq.com/articles/fda-grants-agios-agio-leukemia-candidate-priority-review-2018-02-16", "https://www.nasdaq.com/articles/celgene-celg-q4-preview%3A-will-it-beat-on-earnings-again-2018-01-22", "https://www.nasdaq.com/articles/heres-why-agios-agio-stock-is-up-more-than-50-in-a-year-2018-01-19", "https://www.nasdaq.com/articles/health-care-sector-update-01192018-jnj-pfe-abt-mrk-amgn-pavm-acor-obln-agio-chek-2018-01", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-agios-pharmaceuticals-earns-81-rs-rating-2018", "https://www.nasdaq.com/articles/celgene-provides-2017-preliminary-results-2018-view-2018-01-09", "https://www.nasdaq.com/articles/celgene-to-acquire-impact-biomedicines-to-boost-pipeline-2018-01-08", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-151-2018-01-08", "https://www.nasdaq.com/articles/whats-in-the-cards-for-varian-medical-var-in-q1-earnings-2018-01-22", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-shares-cross-below-200-dma-2017-12-29", "https://www.nasdaq.com/articles/agios-agio-files-nda-for-leukemia-candidate-in-the-u.s.-2017-12-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-biib-celg-hit-pipeline-news-acquisition-deals-ignyta-sucampo-2017-12", "https://www.nasdaq.com/articles/celgene-celg-down-on-discouraging-data-on-revlimid-2017-12-22", "https://www.nasdaq.com/articles/agios-pharmaceuticals-now-oversold-agio-2017-12-14", "https://www.nasdaq.com/articles/why-biotech-stock-defying-hematology-related-pitfall-2017-12-12", "https://www.nasdaq.com/articles/ibd-rating-upgrades-agios-pharmaceuticals-flashes-improved-relative-price-strength-2017-12", "https://www.nasdaq.com/articles/celgene-celg-in-troubled-waters-in-17%3A-what-does-2018-hold-2017-12-29", "https://www.nasdaq.com/articles/agios-posts-new-data-on-glioma-candidate-from-dose-expansion-2017-11-20", "https://www.nasdaq.com/articles/7-strong-buy-stocks-with-100-wall-street-support-2017-11-17", "https://www.nasdaq.com/articles/health-care-sector-update-11172017-agio-2017-11-17", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-avgo-agio-rdfn-2017-11-09", "https://www.nasdaq.com/articles/agios-agio-q3-loss-narrower-than-expected-revenues-up-y-y-2017-11-02", "https://www.nasdaq.com/articles/agios-agio-q3-loss-narrower-than-expected-sales-beat-2017-11-01", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q3-earnings%3A-whats-in-store-2017-10-27", "https://www.nasdaq.com/articles/agios-pharmaceuticals-enters-oversold-territory-agio-2017-11-20", "https://www.nasdaq.com/articles/celgene-celg-tops-q3-earnings-sales-miss-updates-view-2017-10-26", "https://www.nasdaq.com/articles/is-celgene-celg-poised-for-a-beat-this-earnings-season-2017-10-23", "https://www.nasdaq.com/articles/agios-pharmaceuticals-inc-agio-ceo-david-p-schenkein-sold-56-million-shares-2017-10-05", "https://www.nasdaq.com/articles/we-did-math-fbt-can-go-141-2017-09-25", "https://www.nasdaq.com/articles/why-you-can-back-truck-and-load-biotech-stock-2017-08-27", "https://www.nasdaq.com/articles/analysts-expect-eqwm-will-reach-49-2017-08-16", "https://www.nasdaq.com/articles/why-i-love-celgene-corporation-2017-08-15", "https://www.nasdaq.com/articles/commit-purchase-agios-pharmaceuticals-55-earn-156-annualized-using-options-2017-10-26", "https://www.nasdaq.com/articles/agios-agio-q2-loss-wider-than-expected-sales-miss-2017-08-08", "https://www.nasdaq.com/articles/med-product-stocks-aug-8-earnings-roster%3A-hsic-agio-more-2017-08-07", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-agios-pharmaceuticals-agio-this-earnings-season-2017-08-07", "https://www.nasdaq.com/articles/4-medical-product-stocks-likely-to-top-q2-earnings-estimates-2017-08-07", "https://www.nasdaq.com/articles/will-expenses-hit-envision-healthcare-evhc-q2-earnings-2017-08-04", "https://www.nasdaq.com/articles/agios-pharmaceuticals-reaches-analyst-target-price-2017-08-03", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-looks-good%3A-stock-adds-5.1-in-session-2017-08-03", "https://www.nasdaq.com/articles/agios-agio-q2-loss-wider-than-expected-revenues-up-y-y-2017-08-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-gilead-celg-more-dynavax-panel-vote-2017-08-02", "https://www.nasdaq.com/articles/key-fda-events-watch-out-aug-2017-2017-08-01", "https://www.nasdaq.com/articles/celgene-celg-beats-q2-earnings-sales-estimates-ups-view-2017-07-27", "https://www.nasdaq.com/articles/commit-purchase-agios-pharmaceuticals-45-earn-109-annualized-using-options-2017-07-26", "https://www.nasdaq.com/articles/whats-in-store-for-agios-pharma-agio-in-q2-earnings-2017-07-26", "https://www.nasdaq.com/articles/is-celgene-celg-poised-for-a-beat-this-earnings-season-2017-07-24", "https://www.nasdaq.com/articles/celgene-celg-beigene-team-up-for-pd-1-inhibitor-in-china-2017-07-06", "https://www.nasdaq.com/articles/3-reasons-best-yet-come-celgene-2017-08-02", "https://www.nasdaq.com/articles/celgene-celg-reports-data-on-lupus-drug-in-phase-ii-trial-2017-06-15", "https://www.nasdaq.com/articles/agios-agio-up-2.6-since-earnings-report%3A-can-it-continue-2017-06-08", "https://www.nasdaq.com/articles/celgene-and-agios-announce-data-on-idhifa-for-leukemia-2017-06-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-vyxeos-nda-granted-priority-review-2017-06-01", "https://www.nasdaq.com/articles/math-shows-iyh-can-go-175-2017-05-30", "https://www.nasdaq.com/articles/3-stocks-buy-when-markets-crashing-2017-05-18", "https://www.nasdaq.com/articles/agios-agio-q1-loss-narrower-than-expected-indhifa-in-focus-2017-05-05", "https://www.nasdaq.com/articles/agios-celgenes-leukemia-candidate-positive-in-phase-i-ii-2017-06-27", "https://www.nasdaq.com/articles/3-debt-free-clinical-stage-biotech-stocks-are-swimming-cash-2017-05-03", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q1-earnings%3A-whats-in-store-2017-05-01", "https://www.nasdaq.com/articles/celgene-celg-tops-on-q1-earnings-sales-miss-raises-view-2017-04-27", "https://www.nasdaq.com/articles/1-stock-id-buy-right-now-2017-04-26", "https://www.nasdaq.com/articles/commit-buy-agios-pharmaceuticals-35-earn-94-annualized-using-options-2017-04-25", "https://www.nasdaq.com/articles/liberty-sirius-xm-group-lsxmk-lead-12-activist-investor-reports-2017-04-25", "https://www.nasdaq.com/articles/key-factors-look-out-celgenes-celg-q1-results-2017-04-25", "https://www.nasdaq.com/articles/agios-agio-q1-loss-narrower-than-expected-sales-down-y-y-2017-05-04", "https://www.nasdaq.com/articles/tuesdays-etf-movers-itb-fbt-2017-04-18", "https://www.nasdaq.com/articles/3-cancer-drug-stocks-could-make-you-rich-2017-04-17", "https://www.nasdaq.com/articles/3-rock-solid-stocks-buy-next-market-crash-2017-04-13", "https://www.nasdaq.com/articles/3-perfect-stocks-you-can-buy-now-2017-04-07", "https://www.nasdaq.com/articles/analysts-anticipate-fbt-will-reach-122-2017-03-23", "https://www.nasdaq.com/articles/why-is-agios-agio-up-8.5-since-the-last-earnings-report-2017-03-20", "https://www.nasdaq.com/articles/mondays-etf-movers-fbt-xrt-2017-03-20", "https://www.nasdaq.com/articles/9-reasons-celgene-could-be-worlds-most-perfect-stock-2017-04-24", "https://www.nasdaq.com/articles/agios-agio-q4-loss-narrower-than-expected-revenues-up-y-y-2017-02-16", "https://www.nasdaq.com/articles/implied-iyh-analyst-target-price-169-2017-02-16", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2017-02-10", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-agios-pharmaceuticals-agio-2017-01-13", "https://www.nasdaq.com/articles/commit-purchase-agios-pharmaceuticals-35-earn-178-annualized-using-options-2017-01-10", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-sank-344-2016-2017-01-10", "https://www.nasdaq.com/articles/implied-iyh-analyst-target-price-169-2017-01-09", "https://www.nasdaq.com/articles/agios-pharma-agio-q4-loss-narrower-than-expected-stock-up-2017-02-17", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-inc-got-hammered-today-2016-12-16", "https://www.nasdaq.com/articles/health-care-sector-update-12162016-agioevokrxii-2016-12-16", "https://www.nasdaq.com/articles/3-drugs-heading-fda-soon-2016-12-12", "https://www.nasdaq.com/articles/agios-presents-data-from-dose-expansion-study-of-ag-120-2016-11-21", "https://www.nasdaq.com/articles/agios-pharmaceuticals-reaches-analyst-target-price-2016-11-15", "https://www.nasdaq.com/articles/agios-agio-posts-wider-than-expected-loss-in-q3-2016-11-03", "https://www.nasdaq.com/articles/why-celgene-corp-better-buy-gilead-sciences-2016-11-03", "https://www.nasdaq.com/articles/agios-stops-development-of-pkr-activator-ag-519-stock-falls-2016-12-19", "https://www.nasdaq.com/articles/agios-agio%3A-will-the-stock-disappoint-in-q3-earnings-2016-10-31", "https://www.nasdaq.com/articles/celgene-agios-ink-deals-with-abbott-to-identify-idh-mutations-2016-10-13", "https://www.nasdaq.com/articles/celgene-smartest-buyer-biotech-2016-09-30", "https://www.nasdaq.com/articles/analysts-forecast-14-upside-iyh-2016-09-27", "https://www.nasdaq.com/articles/agios-agio-partner-celgene-to-file-for-enasidenib-stock-up-2016-09-08", "https://www.nasdaq.com/articles/wednesdays-etf-movers-fbt-gdxj-2016-09-07", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-trgp-agio-wfm-2016-09-07", "https://www.nasdaq.com/articles/medical-product-nov-3-earnings-preview%3A-hrc-agio-pen-podd-2016-11-02", "https://www.nasdaq.com/articles/1-stock-youve-been-overlooking-your-roth-ira-2016-08-11", "https://www.nasdaq.com/articles/agios-agio-q2-loss-wider-than-expected-pipeline-in-focus-2016-08-05", "https://www.nasdaq.com/articles/agios-agio-reports-wider-than-expected-loss-in-q2-2016-08-04", "https://www.nasdaq.com/articles/medical-product-stock-earnings-on-aug-4%3A-nxtm-agio-more-2016-08-03", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-estimates-in-q2-earnings-2016-08-02", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-sale-2016-07-30", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-inc-stock-skyrocketed-today-2016-09-07", "https://www.nasdaq.com/articles/3-big-reasons-agios-pharmaceuticals-inc-has-plunged-38-2016-2016-07-03", "https://www.nasdaq.com/articles/commit-purchase-agios-pharmaceuticals-35-earn-156-annualized-using-options-2016-06-21", "https://www.nasdaq.com/articles/agios-reports-favorable-phase-ii-pk-deficiency-study-data-2016-06-13", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-stock-rose-143-may-2016-06-10", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-inc-presented-lower-today-2016-06-09", "https://www.nasdaq.com/articles/thursdays-etf-movers-gdxj-xbi-2016-06-09", "https://www.nasdaq.com/articles/agio-crosses-above-key-moving-average-level-2016-06-02", "https://www.nasdaq.com/articles/first-week-july-15th-options-trading-agios-pharmaceuticals-agio-2016-07-14", "https://www.nasdaq.com/articles/health-care-sector-update-05182016-agiocelgpetxmtp-2016-05-18", "https://www.nasdaq.com/articles/agios-agio-q1-loss-lower-than-expected-pipeline-in-focus-2016-05-06", "https://www.nasdaq.com/articles/agios-agio-reports-narrower-than-expected-loss-in-q1-2016-05-05", "https://www.nasdaq.com/articles/whats-in-store-for-agios-agio-this-earnings-season-2016-05-03", "https://www.nasdaq.com/articles/mylan-myl-q1-earnings%3A-whats-in-the-cards-for-the-stock-2016-04-28", "https://www.nasdaq.com/articles/merrimack-mack-q1-earnings%3A-whats-ahead-for-the-stock-2016-04-27", "https://www.nasdaq.com/articles/prothena-prta%3A-whats-ahead-for-the-stock-in-q1-earnings-2016-04-27", "https://www.nasdaq.com/articles/agios-strikes-metabolic-immuno-oncology-deal-with-celgene-2016-05-18", "https://www.nasdaq.com/articles/first-week-november-18th-options-trading-agios-pharmaceuticals-agio-2016-03-23", "https://www.nasdaq.com/articles/interesting-agio-put-and-call-options-april-15th-2016-02-25", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-22nd-2016-02-22", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-pipeline-in-focus-2016-02-19", "https://www.nasdaq.com/articles/agios-agio-reports-wider-than-expected-loss-in-q4-2016-02-18", "https://www.nasdaq.com/articles/health-care-sector-update-02182016-agio-zfgn-2016-02-18", "https://www.nasdaq.com/articles/agios-agio-q4-earnings-preview%3A-will-it-disappoint-again-2016-02-16", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-xlu-2016-04-06", "https://www.nasdaq.com/articles/top-biotechs-2016-2016-01-28", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xop-fbt-2016-01-26", "https://www.nasdaq.com/articles/health-care-sector-update-01212016-agio-acrx-2016-01-21", "https://www.nasdaq.com/articles/xbi-cphd-agio-mdvn-large-outflows-detected-etf-2016-01-12", "https://www.nasdaq.com/articles/agios-agio-provides-pipeline-updates-and-2016-strategy-2016-01-12", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xbi-agio-cphd-rare-2016-01-04", "https://www.nasdaq.com/articles/tuesdays-etf-movers-oih-xbi-2015-12-22", "https://www.nasdaq.com/articles/silly-reason-why-agios-pharmaceuticals-inc-was-clobbered-january-2016-02-06", "https://www.nasdaq.com/articles/expectations-perfection-haunt-agios-pharmaceuticals-inc-november-2015-12-09", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-ebix-deck-agio-2015-12-07", "https://www.nasdaq.com/articles/second-cancer-incidence-rates-have-doubled-and-catch-22-has-emerged-2015-12-06", "https://www.nasdaq.com/articles/1-healthcare-stock-has-it-all-2015-11-26", "https://www.nasdaq.com/articles/health-care-sector-update-11092015-agioloxoavxl-2015-11-09", "https://www.nasdaq.com/articles/agios-agio-q3-loss-wider-than-expected-pipeline-in-focus-2015-11-06", "https://www.nasdaq.com/articles/agios-agio-reports-wider-than-expected-loss-in-q3-2015-11-05", "https://www.nasdaq.com/articles/3-most-important-drugs-celgenes-pipeline-2015-12-21", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-in-focus%3A-stock-rises-24.8-2015-10-28", "https://www.nasdaq.com/articles/health-care-sector-update-10272015-agiotrivelgxorpn-2015-10-27", "https://www.nasdaq.com/articles/health-care-sector-update-10272015-agiotrivelgxorpn-2015-10-27-0", "https://www.nasdaq.com/articles/tuesdays-etf-movers-fbt-xop-2015-10-27", "https://www.nasdaq.com/articles/first-week-december-18th-options-trading-agios-pharmaceuticals-agio-2015-10-22", "https://www.nasdaq.com/articles/agios-agio-provides-pipeline-update-ag-221-in-focus-2015-10-22", "https://www.nasdaq.com/articles/agios-pharmaceuticals-enters-oversold-territory-agio-2015-09-29", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-investors-this-earnings-season-2015-11-04", "https://www.nasdaq.com/articles/agios-pharmaceuticals-now-oversold-agio-2015-08-14", "https://www.nasdaq.com/articles/agios-pharmaceuticals-breaks-below-200-day-moving-average-notable-agio-2015-08-06", "https://www.nasdaq.com/articles/dexcom-dxcm-q2-loss-wider-than-expected-revenues-beat-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/has-allscripts-q2-earnings-results-disappointed-investors-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/agios-agio-reports-wider-than-expected-loss-in-q2-tale-of-the-tape-2015-08-06", "https://www.nasdaq.com/articles/surmodics-srdx-beats-on-q3-earnings-improves-outlook-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/alere-lags-q2-earnings-revenues-down-y-y-margins-expand-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/first-week-agio-october-16th-options-trading-2015-09-28", "https://www.nasdaq.com/articles/pacific-biosciences-pacb-q2-earnings%3A-whats-in-store-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/outfront-media-out-to-report-earnings%3A-what-to-expect-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/is-agios-agio-poised-to-beat-estimates-in-q2-earnings-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/3-medtech-stocks-to-buy-before-their-q2-earnings-earnings-esp-2015-08-04", "https://www.nasdaq.com/articles/community-health-q2-earnings-beat-surge-y-y-view-revised-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/luminex-lmnx-tops-q2-earnings-revenues-pipeline-strong-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/will-ariad-aria-disappoint-estimates-this-earnings-season-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/thoratec-beats-on-q2-earnings-revenues-pipeline-strong-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-beat-earnings-in-q2-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-beat-q2-earnings-estimates-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/will-cerners-cern-earnings-pull-a-surprise-in-q2-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/will-biomarin-top-q2-earnings-again-on-vimizim-sales-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/will-dentsply-xray-beat-earnings-on-pipeline-strength-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/can-cardinal-healths-cah-q4-earnings-pull-a-surprise-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/will-ecolab-ecl-earnings-take-investors-by-surprise-in-q2-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/will-becton-dickinson-bdx-earnings-pull-a-surprise-in-q3-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/xoma-crashes-after-gevokizumab-misses-primary-endpoint-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/eli-lilly-biogen-present-data-at-alzheimers-association-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/abbvie-neurodegenerative-disorder-drug-gets-orphan-status-analyst-blog-2015-07-20", "https://www.nasdaq.com/articles/can-c.r.-bard-bcr-surprise-earnings-estimates-in-q2-analyst-blog-2015-07-20", "https://www.nasdaq.com/articles/astrazeneca-strikes-deal-to-market-benralizumab-in-japan-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/amgen-reports-positive-data-on-leukemia-drug-blincyto-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/hill-rom-welch-allyn-acquisition-deal-wins-ftc-clearance-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/st.-jude-to-acquire-thoratec-for-%243.4b%3A-potent-combination-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/astrazenecas-azn-oncology-drug-iressa-label-expanded-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/abbvie-abbv-gains-on-label-expansion-of-imbruvica-in-eu-analyst-blog-2015-07-13", "https://www.nasdaq.com/articles/tg-therapeutics-tgtx-looks-good%3A-stock-adds-5.8-tale-of-the-tape-2015-07-10", "https://www.nasdaq.com/articles/astrazeneca-divests-ex-u.s.-rights-to-entocort-for-%24215m-analyst-blog-2015-07-10", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-baxter-international-bax-tale-of-the-tape-2015-07-09", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-july-8th-tale-of-the-tape-2015-07-08", "https://www.nasdaq.com/articles/agios-doses-first-patient-with-ag-881-in-early-stage-study-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/2-reasons-why-medtronic-should-draw-investors-attention-now-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-losing-money-wed-still-buy-them-2015-06-21", "https://www.nasdaq.com/articles/agios-reports-new-data-on-hematologic-malignancy-drugs-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-inc-shares-were-throttled-2015-06-12", "https://www.nasdaq.com/articles/fridays-etf-movers-fm-fbt-2015-06-12", "https://www.nasdaq.com/articles/agios-gets-orphan-drug-designation-from-fda-for-ag-120-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-agios-pharmaceuticals-agio-stock-tale-of-the-tape-2015-05-28", "https://www.nasdaq.com/articles/use-options-chance-buy-agio-25-discount-2015-05-27", "https://www.nasdaq.com/articles/2-stocks-buy-now-biotech-2015-06-22", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-losing-money-wed-still-buy-them-2015-06-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-eleven-bio-slumps-eye-drug-data-achillion-signs-deal-jj-analyst-blog", "https://www.nasdaq.com/articles/agios-gains-on-fast-track-status-for-leukemia-drug-ag-120-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-agio-could-be-positioned-for-a-surge-tale-of-the-tape-2015-05-15", "https://www.nasdaq.com/articles/company-news-for-may-08-2015-corporate-summary-2015-05-08", "https://www.nasdaq.com/articles/agios-agio-reports-narrower-than-expected-loss-in-q1-tale-of-the-tape-2015-05-07", "https://www.nasdaq.com/articles/mutual-fund-manager-columbia-wanger-adds-4-stocks-q1-2015-05-05", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-agios-pharmaceuticals-agio-tale-of-the-tape-2015-05-27", "https://www.nasdaq.com/articles/health-care-sector-update-04302015-wx-agio-cah-2015-04-30", "https://www.nasdaq.com/articles/biotech-bubble-bursting-3-stocks-i-want-buy-2015-04-27", "https://www.nasdaq.com/articles/commit-purchase-agios-pharmaceuticals-80-earn-216-annualized-using-options-2015-04-14", "https://www.nasdaq.com/articles/agios-pk-deficiency-drug-ag-348-gets-orphan-drug-status-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/what-makes-agios-pharmaceuticals-agio-a-strong-sell-tale-of-the-tape-2015-02-24", "https://www.nasdaq.com/articles/1-stock-youve-been-overlooking-your-roth-ira-2015-02-20", "https://www.nasdaq.com/articles/company-news-for-february-18-2015-corporate-summary-2015-02-18", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-this-earnings-season-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/agios-agio-reports-wider-than-expected-loss-in-q4-tale-of-the-tape-2015-02-17", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-inc-shares-burst-today-2015-02-17", "https://www.nasdaq.com/articles/will-agios-agio-surprise-estimates-this-earnings-season-analyst-blog-2015-02-16", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-17-2015-mdt-wm-gpc-mgm-nclh-gt-leco-wri-agio-www-nhi", "https://www.nasdaq.com/articles/7-companies-wed-buy-and-hold-next-20-years-2015-02-06", "https://www.nasdaq.com/articles/top-healthcare-stock-buy-february-2015-02-01", "https://www.nasdaq.com/articles/celgene-corps-expanding-margins-2015-01-29", "https://www.nasdaq.com/articles/health-care-sector-update-02172015-agio-pfe-2015-02-17", "https://www.nasdaq.com/articles/companys-first-profit-can-mean-big-profits-investors-screen-week-2015-01-13", "https://www.nasdaq.com/articles/why-agios-pharmaceuticals-agio-could-be-positioned-for-a-surge-tale-of-the-tape-2015-01-12", "https://www.nasdaq.com/articles/surprising-thing-most-2014s-top-10-stocks-have-common-2015-01-11", "https://www.nasdaq.com/articles/these-3-biotech-stocks-tripled-investors-money-2014-2015-01-04", "https://www.nasdaq.com/articles/markets-top-10-stocks-2014-2015-01-03", "https://www.nasdaq.com/articles/these-3-biotechs-are-looking-happy-new-year-2014-12-31", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xbi-agio-blue-rcpt-2014-12-24", "https://www.nasdaq.com/articles/5-cant-miss-reasons-why-celgene-corporation-could-soar-2015-01-26", "https://www.nasdaq.com/articles/3-traits-best-healthcare-stocks-2014-2014-12-15", "https://www.nasdaq.com/articles/use-options-chance-buy-agio-32-discount-2014-12-12", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-looks-good%3A-stock-up-6.9-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/futures-lower-global-growth-concerns-triggered-overseas-2014-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12082014-aria-agio-adxs-knd-2014-12-08", "https://www.nasdaq.com/articles/agios-agio-reports-encouraging-data-on-leukemia-drug-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-could-pay-dividends-wont-2014-12-07", "https://www.nasdaq.com/articles/tuesday-sector-laggards-drugs-biotechnology-stocks-2014-12-23", "https://www.nasdaq.com/articles/agios-agio-shares-up-on-positive-ag-120-study-data-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/health-care-sector-update-11192014-agioaemdbind-2014-11-19", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-in-the-q3-earnings-season-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-7-2014-bam-hum-bpl-icpt-isis-stay-agio-erf-lxp-ctb-sji", "https://www.nasdaq.com/articles/can-celgene-corporation-stock-motor-150-following-earnings-2014-10-28", "https://www.nasdaq.com/articles/forget-mannkind-corporation-3-better-stocks-2014-10-27", "https://www.nasdaq.com/articles/agios-agio-rises-on-expansion-of-phase-i-study-on-ag-221-analyst-blog-2014-10-16", "https://www.nasdaq.com/articles/3-top-large-cap-biotech-stocks-2015-2014-12-06", "https://www.nasdaq.com/articles/agios-agio-shares-up-on-positive-ag-120-study-data-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-26-0", "https://www.nasdaq.com/articles/nasdaq-biotech-top-performers-pre-open-september-19-2014-09-19", "https://www.nasdaq.com/articles/agios-pharmaceuticals-director-buys-2300-shares-2014-06-25", "https://www.nasdaq.com/articles/wednesday-625-insider-buying-report-saft-agio-2014-06-25", "https://www.nasdaq.com/articles/mondays-etf-movers-gdxj-ibb-2014-06-23", "https://www.nasdaq.com/articles/agios-to-present-data-on-ag-120-in-november-shares-rises-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/agios-initiates-trial-on-ag-348-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/friday-52-insider-buying-report-oksb-agio-2014-05-02", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-tuesday-tale-of-the-tape-2014-04-29", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-crumbles%3A-stock-falls-by-6.0-tale-of-the-tape-2014-04-25", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-mixed-pre-market-quest-diagnostic-results-top-street-view", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-24-1", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-soars-panel-vote-halozyme-plunges-safety-concerns-analyst", "https://www.nasdaq.com/articles/agios-presents-data-on-ag-221-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-04-07", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-tuesday-tale-of-the-tape-2014-03-25", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-thursday-tale-of-the-tape-2014-03-13", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-in-focus%3A-stock-tumbles-8.1-tale-of-the-tape-2014-03-12", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-03-10", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-surges%3A-stock-moves-26.2-higher-tale-of-the-tape-2014-03-07", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-ibb-2014-03-07", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-surges%3A-stock-moves-27.8-higher-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-06-0", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-surges%3A-stock-moves-18.6-higher-tale-of-the-tape-2014-01-16", "https://www.nasdaq.com/articles/biotech-ipos-are-back-normal-2013-11-25", "https://www.nasdaq.com/articles/pipeline-progress-at-agios-pharma-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/us-ipo-recap-11-deals-price-busiest-week-november-2007-seven-companies-set-terms-2013-07", "https://www.nasdaq.com/articles/agios-pharmaceuticals-prices-ipo-18-above-range-2013-07-24", "https://www.nasdaq.com/articles/agios-pharmaceuticals-gains-almost-74-market-debut-biotech-fever-continues-2013-07-24", "https://www.nasdaq.com/articles/healthcare-stocks-turn-lower-afternoon-agios-pharma-climbs-after-beating-q4-revenue", "https://www.nasdaq.com/articles/12-us-ipos-planned-week-jul-22-2013-07-22", "https://www.nasdaq.com/articles/biotech-agios-pharmaceuticals-sets-terms-75-million-ipo-2013-07-12", "https://www.nasdaq.com/articles/four-more-ipos-today-2013-07-24"], "Content": []}